Related Experiment Video
Updated: Jan 21, 2026

Electrospinning Growth Factor Releasing Microspheres into Fibrous Scaffolds
Published on: August 16, 2014
Sustained Release of Basic Fibroblast Growth Factor (bFGF) Encapsulated Polycaprolactone (PCL) Microspheres Promote
Pala Arunkumar1, Julie A Dougherty1, Jessica Weist1
1Department of Emergency Medicine, College of Medicine, Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Polycaprolactone microspheres successfully delivered basic fibroblast growth factor (bFGF) for 30 days, promoting angiogenesis and cell survival. This bFGF-PCL-MS formulation shows promise for treating myocardial infarction.
Area of Science:
- Biomaterials Engineering
- Cardiovascular Research
- Regenerative Medicine
Background:
- Coronary heart disease (CHD) is a leading global cause of mortality.
- Myocardial infarction (MI) treatment strategies focus on preserving cardiac function using growth factors.
- Basic fibroblast growth factor (bFGF) exhibits angiogenic potential but suffers from poor clinical efficacy due to short half-life and low stability.
Purpose of the Study:
- To develop bFGF-loaded polycaprolactone (PCL) microspheres (bFGF-PCL-MS) for sustained bFGF release.
- To evaluate the angiogenic potential of bFGF-PCL-MS both in vitro and in vivo.
Main Methods:
- Fabrication of bFGF-PCL-MS using emulsion solvent-evaporation method.
- In vitro assessment of bFGF release kinetics over 30 days.
- In vitro evaluation of HUVEC proliferation, migration, and angiogenic gene expression.
- In vivo assessment of angiogenic potential in a rat Matrigel plug assay.
Main Results:
- bFGF-PCL-MS exhibited spherical morphology (4.21 ± 1.28 µm) and sustained bFGF release for up to 30 days.
- In vitro studies demonstrated enhanced HUVEC proliferation, migration, and increased expression of angiogenic genes (bFGF, VEGFA).
- In vivo assays confirmed increased expression of angiogenic markers, validating the angiogenic potential of bFGF-PCL-MS.
Conclusions:
- Sustained release of bFGF from PCL microspheres enhances angiogenic properties.
- bFGF-PCL-MS represent a promising strategy for promoting angiogenesis and cell survival post-myocardial infarction.
- This formulation could improve therapeutic outcomes for patients with acute myocardial infarction.
More Related Videos
09:31Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
05:43Preparation of Giant Vesicles Encapsulating Microspheres by Centrifugation of a Water-in-oil Emulsion
Published on: January 24, 2017
Related Concept Videos
Sustainable Development
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Factors Influencing Microbial Growth: pH
Factors Influencing Microbial Growth: Temperature
Factors Influencing Microbial Growth: Osmolarity
The Eukaryotic Promoter Region